Voloridge Investment Management
FDMT icon

Voloridge Investment Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Voloridge Investment Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-84,175
Closed -$272K – 1235
2025
Q1 		$272K Sell
84,175
-99,724
-54% -$470K ﹤0.01% 1128
2024
Q4 		$1.02M Sell
183,899
-106,132
-37% -$833K ﹤0.01% 1037
2024
Q3 		$3.14M Sell
290,031
-71,666
-20% -$1.19M 0.01% 867
2024
Q2 		$7.59M Sell
361,697
-19,382
-5% -$486K 0.03% 641
2024
Q1 		$12.1M Buy
381,079
+361,385
+1,835% +$9.22M 0.04% 439
2023
Q4 		$399K Sell
19,694
-53,073
-73% -$698K ﹤0.01% 1053
2023
Q3 		$926K Sell
72,767
-62,894
-46% -$1.05M ﹤0.01% 1112
2023
Q2 		$2.45M Buy
135,661
+23,563
+21% +$434K 0.01% 928
2023
Q1 		$1.93M Buy
+112,098
New +$2.18M 0.01% 986

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management's FDMT Position: Q2 2025 in Review

Voloridge Investment Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 84,175 shares — an estimated $272K sold.

Voloridge Investment Management first reported a position in FDMT in Q1 2023 and held it in 9 quarters. The position peaked at $12.1M in Q1 2024. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

  • Voloridge Investment Management reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 84,175 4D Molecular Therapeutics shares in Q2 2025, an estimated $272K.
  • Voloridge Investment Management first reported a position in 4D Molecular Therapeutics in Q1 2023 and held it in 9 quarters.
  • Voloridge Investment Management's 4D Molecular Therapeutics position peaked at $12.1M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on Voloridge Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.